Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. - Wikidata - awgldk - TriplyDB

Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy.

Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy.

http://www.wikidata.org/entity/Q33383664

about

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy.Hematologic toxicities of small molecule tyrosine kinase inhibitors.Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia.Gastrointestinal bleeding in a chronic myeloid leukaemia patient precipitated by dasatinib-induced platelet dysfunction: Case report.Selecting the best frontline treatment in chronic myeloid leukemia First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.Practical management of patients with chronic myeloid leukemia.Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.Moving on up: Second-Line Agents as Initial Treatment for Newly-Diagnosed Patients with Chronic Phase CML.Chronic myeloid leukemia: mechanisms of resistance and treatment.Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?A Study of Haemostatic Parameters in Patients of Chronic Myeloid Leukaemia.Dasatinib-induced haemorrhagic colitis in chronic myeloid leukaemia (CML) in blast crisis.Bosutinib Therapy in Patients With Chronic Myeloid Leukemia: Practical Considerations for Management of Side Effects.Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications.Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia.Evolution of therapies for chronic myelogenous leukemia.Dasatinib for the treatment of Philadelphia chromosome-positive leukemias.Chronic myeloid leukemia: overview of new agents and comparative analysis.The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients.Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors.Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management.Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients.Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia.Chronic myeloid leukemia: Second-line drugs of choice.The Safety of Bosutinib for the Treatment of Chronic Myeloid Leukemia.Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.Dasatinib-Induced CMV Hepatitis in an Immunocompetent Patient: A Rare Complication of a Common Drug.Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring.Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance.Haemorrhagic colitis caused by dasatinib.Protein-coding genes and long noncoding RNAs are differentially expressed in dasatinib-treated chronic myeloid leukemia patients with resistance to imatinib.Dasatinib-induced hemorrhagic colitis complicated with cytomegalovirus infection.Tyrosine Kinase Inhibitors in the Treatment of Chronic-Phase CML: Strategies for Frontline Decision-making.Tumor lysis syndrome soon after treatment with hydroxyurea followed by nilotinib in two patients with chronic-phase chronic myelogenous leukemia.Optimal management for pediatric chronic myeloid leukemia.

P2860

Q26749324-757DD8A1-902C-4B09-BD02-B6EB53CD9170 Q28079372-463773FE-6B84-4189-AE3E-B4105BA7DEA9 Q33392977-BC499A4A-3AAE-493E-8CE1-FB9AF17AD43C Q33395138-486554DE-7F62-4CFB-AC7D-A0407731CADD Q33398485-F4FE63CF-7D37-4361-B1FF-73417F1D4321 Q33401360-6B7A37D5-DB53-4AF1-9A6D-3B0FC99495E4 Q33423255-79296E45-468E-484F-895A-56C885DC2873 Q33764253-0013BB3A-0388-44C1-B770-5B208A4C6800 Q33843477-29EE252B-1595-41F4-B6E8-104EA16C117A Q33849146-77C1DB8D-C0E9-44FB-BEBC-377BAEA68EDE Q33878636-9B759B67-1AE4-4DDC-BAE7-B790AD359709 Q35117747-BE7C75D3-EF8C-4C3E-BDF8-5E52088D10B1 Q35595795-5C53E535-E563-4965-8CAC-EB308EFCE7E2 Q35595870-6F566AA5-32CF-4E70-BE9B-0EA15A2C4E36 Q36545339-5DDF3F9F-754A-474C-916D-CA990CE5EF44 Q37250755-E9628B7C-341E-4325-9564-B80ED5A8001C Q37391786-FF5A189E-A930-43C1-B529-88200A7CE6EC Q37579983-5A2E662E-B4CB-48AC-9576-80BA7464D9EB Q37797981-3BF3D6A9-BE35-46F0-ACAB-35A35F086755 Q37827278-58F9E1BA-13AA-4D05-A8DD-2A17D41C7E6B Q37966915-A1421A00-745A-462A-BE29-E4F2FA520C56 Q38044753-002A6CB3-F019-4797-93F5-411BBCDCCA92 Q38097728-B3553EC8-4DD5-44CD-ABA0-D1B1BE6C4D04 Q38128723-C0A81C2F-333A-4902-9740-4E91FCE03153 Q38148243-E0EFE1A5-03E0-435A-9C19-1BC8665F9E1C Q38204330-A915FA20-EE06-49EF-B9CB-E56A84959FBB Q38392673-5804B56B-0D4E-41AB-934F-1AAE1F84B9FA Q38392679-A559230D-2D2D-443C-B335-EBF461740E2C Q38640422-F4DD8DCF-8A4C-4958-A005-70353FEFE43F Q38642952-8F118A1E-9B4C-4CC4-A2FD-BF6166D5962D Q38753313-C32A356E-73F2-4FD0-9186-3A9FAD648988 Q40643461-423FB706-C8B8-45D5-A3F6-8A15533E28C0 Q40957470-570D0CD4-CF22-4803-9699-2F1367C3755B Q41348012-6F0EA34B-12CB-4E8B-B87E-001651A70409 Q42562106-1E43347B-6CD2-4BF5-93F7-D82E281EB13A Q46970334-9A99D3FD-E613-4B34-A15E-D533D90AC541 Q50050031-3812E94C-570E-4E5F-AAE9-974124A6D6F6 Q52567954-07E23618-2568-4578-B884-0AEA2A062201 Q54432465-769A7317-4400-42C1-A77A-2B2A5885CD22 Q55034870-63425310-052F-44AE-B0EF-5BD0A0A2FF32

P2860

Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy.

http://www.wikidata.org/entity/Q33383664

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Bleeding diathesis in patients ...... a receiving dasatinib therapy.

@ast

Bleeding diathesis in patients ...... a receiving dasatinib therapy.

@en

type

label

Bleeding diathesis in patients ...... a receiving dasatinib therapy.

@ast

Bleeding diathesis in patients ...... a receiving dasatinib therapy.

@en

prefLabel

Bleeding diathesis in patients ...... a receiving dasatinib therapy.

@ast

Bleeding diathesis in patients ...... a receiving dasatinib therapy.

@en

P1433

Q33383664-5027E068-1FCA-4F77-A3AF-F172BBE3CA2B

P1476

Q33383664-826F2B30-F7AE-44F9-9862-2971234A5C64

P2093

Q33383664-3AC95C13-B340-452B-A10B-DAF89BBD6DBE

Q33383664-54A6DCA7-0DEF-44B6-959B-5AC2F7C12FA6

Q33383664-915B1C24-ECC2-4323-86DD-0FC470F6B957

Q33383664-D5EC7B09-35E5-42A1-8CFB-EF0F7FC4074D

P2860

Q33383664-144099F0-B4C2-4E2E-A7E2-624E7CA7F0EE

Q33383664-156BF6B6-E5BC-4997-BC57-6E940232ABBC

Q33383664-32F1434E-E85C-448B-9BF2-6DD6E6A943C8

Q33383664-390E49D7-F688-41D5-AB07-E2F078E13323

Q33383664-4D50F860-F867-493C-9332-AD4ED7A98552

Q33383664-60BB81B1-6A2B-4061-83A9-8FE3C71C2808

Q33383664-6368F5A4-7DE4-4F7B-A3F5-A1C195746678

Q33383664-7213002B-CC21-4812-BCFC-0EB838638064

Q33383664-72E7B6E2-B5EB-44B3-9B18-B101BD962F5F

Q33383664-731AB97B-E21F-47F5-B008-7EE755C50302

P304

Q33383664-989CFCE1-4307-4F24-B7F0-C9937CF24B99

P31

Q33383664-0BE2BC5B-9AD2-43ED-82BF-421667694386

P356

Q33383664-6DDFD446-3B5C-404A-A0E4-CE71F0D564D2

P407

Q33383664-4CB9785B-1CB6-4F32-A320-8EBBD29DAF2C

P433

Q33383664-935A6429-F740-44F0-96FD-AD6098F334C8

P478

Q33383664-D1FD87CA-9341-460E-82F2-26942D38C8D0

P50

Q33383664-3FCC4E94-7766-488C-8C09-8603A47531F7

Q33383664-8A6841C5-0378-4FEF-A5A3-383136E81D6F

Q33383664-8ED88EB9-02C9-4BBA-8A7B-BC672E3F001C

Q33383664-C53E8EC3-5070-4D6F-B96D-0DC0F2C833B7

Q33383664-FB6AA6E2-AFB6-43AF-9789-AFE8E76F9FE7

P577

Q33383664-4145A7BC-BC5D-45F4-A772-0E0A2C7E3C17

P5875

Q33383664-1C959CFA-55E2-4E6D-9EB4-F468D5793B21

P698

Q33383664-FAD2BD9B-39DB-4289-A410-5DA020C58921

P921

Q33383664-4499C1DA-C1D3-4BAA-ABB1-F220B595FD8C

P932

Q33383664-C1D28408-57DB-4E77-BF41-2E2E41F6D80E

P356

P1433

P1476

Bleeding diathesis in patients ...... a receiving dasatinib therapy.

@en

P2093

Alfonso Quintás-Cardama

http://www.w3.org/2001/XMLSchema#string

Deborah Thomas

http://www.w3.org/2001/XMLSchema#string

Gabriela Vidal-Senmache

http://www.w3.org/2001/XMLSchema#string

Steven Kornblau

http://www.w3.org/2001/XMLSchema#string

P2860

Basis of hematopoietic defects in platelet-derived growth factor (PDGF)-B and PDGF beta-receptor null mice

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse

Pericyte loss and microaneurysm formation in PDGF-B-deficient mice

Overriding imatinib resistance with a novel ABL kinase inhibitor

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.

Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib).

P304

2482-2490

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.24257

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

115

http://www.w3.org/2001/XMLSchema#string

P50

Jorge Eduardo Cortes

Hagop Kantarjian

William G Wierda

P577

2009-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24195507

http://www.w3.org/2001/XMLSchema#string

P698

19280591

http://www.w3.org/2001/XMLSchema#string

P921

P932

4180711

http://www.w3.org/2001/XMLSchema#string